Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring ≤3 cm

Abstract

S+ and/or MP+ status predict worse prognosis in patients with acinar- and papillary-predominant lung adenocarcinoma.

Podoplanin expression in cancer‐associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma

“…However, it has been reported that a Japanese cohort of 347 patients with stage IA lung adenocarcinoma had a low frequency (1.7%) of the micropapillary‐predominant pattern, which was similar to the finding in our cohort (1.4%) . Conversely, we have reported previously that the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) predicted a worse prognosis in patients with acinar‐ and papillary‐predominant lung adenocarcinoma measuring ≤3 cm . Therefore, we focused upon the clinical significance of the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) in patients with new TNM p‐stage IA lung adenocarcinoma.…”

“…8 Conversely, we have reported previously that the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) predicted a worse prognosis in patients with acinar-and papillary-predominant lung adenocarcinoma measuring ≤3 cm. 11 Therefore, we focused upon the clinical significance of the presence of solid and/or micropapillary components (≥ 1% of the entire tumour) in patients with new TNM p-stage IA lung adenocarcinoma. The inclusion of both the new TNM classification and well-known established prognostic factors in our analysis strengthened the reliability of our results.…”

“…All cases were classified into five predominant subtypes (lepidic, acinar, papillary, micropapillary and solid) according to the WHO classification of adenocarcinoma . The presence of high‐grade components was defined as having a solid and/or micropapillary component occupying ≥1% of the entire tumour . Written informed consent was obtained, and the present study was approved by the ethics committee of the Faculty of Medicine, Tottori University (approval number: 1704A004; 12 April 2017).…”

“…In turn, it has been reported that the predominant subtype defined by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society (IASLC/ATS/ERS) classification system had prognostic value in patients with stage I lung adenocarcinoma . However, few studies have evaluated the clinical impact of the solid and/or micropapillary component (high‐grade components) . As far as we know, there has been no study validating the clinical value of high‐grade components in patients with new TNM p‐stage IA lung adenocarcinoma.…”

“…[5][6][7][8] However, few studies have evaluated the clinical impact of the solid and/or micropapillary component (high-grade components). [9][10][11] As far as we know, there has been no study validating the clinical value of high-grade components in patients with new TNM p-stage IA lung adenocarcinoma.…”